Discover the Latest Breakthroughs in Endocrinology at ADA Congress: Learn about the First Oral Non-Peptide GLP-1 Agonist and its Impressive Weight Reduction Results!

2023-06-25 14:19:43

Endocrinology – ADA Congress

Orforglipron, the first oral non-peptide GLP-1 agonist, manages to reduce weight by up to 14.7% without restricting eating and drinking hours.

The new oral GLP-1 agonists would be chronic treatments with a similar safety profile to injectables. Photo: SHUTTERSTOCK
1687722754
#Advances #generation #orals #obesity